Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson Disease Research.

ABSTRACT:

Background

Mutations in GBA1, which encodes the lysosome enzyme β-glucocerebrosidase (also referred to as acid β-glucosidase or GCase), are the most common genetic risk factor for Parkinson disease (PD) and dementia with Lewy bodies (DLB). Evidence also suggests that loss of GCase activity is implicated in PD without GBA1 mutations. Consequently, therapies targeting GCase are actively being pursued as potential strategies to modify the progression of PD and related synucleinopathies. Despite this significant interest in GCase as a therapeutic target, the lack of well-characterized GCase antibodies continues to impede progress in the development of GCase-targeted therapies.

Objective

This study aims to independently evaluate human GCase (hGCase) antibodies to pr

SUBMITTER: Jong T 

PROVIDER: S-EPMC10602026 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature